The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
The adjuvant therapy for high risk GIST patients after complete resection in the clinical practice.
 
Toshirou Nishida
Honoraria - Bayer; Novartis; Pfizer
Research Funding - Novartis
 
Masakazu Takagi
No Relationships to Disclose
 
Masato Ozaka
No Relationships to Disclose
 
Yuko Kitagawa
Honoraria - Chugai Pharma; Ethicon; Nippon Kayaku; Olympus; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Ajinomoto (Inst); Asahi Kasei (Inst); Astellas Pharma (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); CSL Behring (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); GlaxoSmithKline (Inst); Kaken Pharmaceutical (Inst); Kowa (Inst); Kureha (Inst); Kyowa Hakko Kirin (Inst); Lilly (Inst); Medtronic (Inst); Merck Serono (Inst); Nippon Kayaku (Inst); Novartis (Inst); Otsuka (Inst); Otsuka (Inst); Pfizer (Inst); Sanofi (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst); Taisho Toyama Pharma (Inst); Takeda (Inst); Teijin Pharma (Inst); Tsumura & Co. (Inst); Yakult Honsha (Inst)
 
Yukinori Kurokawa
Honoraria - Novartis; Pfizer
 
Yoshito Komatsu
Honoraria - Bayer; Novartis; Pfizer
Research Funding - Bayer; Novartis; Pfizer
 
Chikashi Ishioka
Speakers' Bureau - Asahi Kasei; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Merck Serono; Mochida Pharmaceutical Co. Ltd.; Nichi-iko; Novartis; Pfizer; Taiho Pharmaceutical; Takeda
Research Funding - Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Merck Serono; Novartis; Taiho Pharmaceutical; Yakult Pharmaceutical
 
Toshihiko Doi
Consulting or Advisory Role - AstraZeneca; Bayer Yakuhin; Chugai Pharma; Kyowa Hakko Kirin; Lilly Japan; Merck Serono; MSD; Nippon Boehringer Ingelheim; Novartis; Otsuka
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Eisai (Inst); Janssen (Inst); Lilly Japan (Inst); Merck Serono (Inst); MSD (Inst); NanoCarrier (Inst); Novartis (Inst); Pfizer (Inst); Quintiles (Inst); Sanofi (Inst); Sumitomo Group (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Haruhiko Cho
Honoraria - Novartis; Pfizer
 
Tetsuo Kanda
Honoraria - Novartis
 
Toshiro Sugiyama
Research Funding - Novartis; Pfizer
 
Akira Sawaki
Honoraria - Novartis; Pfizer
 
Yoshihiro Kakeji
Honoraria - Takeda
 
Toshihiro Hirai
No Relationships to Disclose
 
Shinji Hato
No Relationships to Disclose
 
Hideo Baba
Honoraria - Novartis; Pfizer
 
Kuniaki Shirao
No Relationships to Disclose
 
Seiichi Hirota
No Relationships to Disclose
 
Tatsuo Kagimura
No Relationships to Disclose
 
Toru Masuzawa
No Relationships to Disclose